REVVITY, INC.
About REVVITY, INC.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.9B
- Net income
- $241.2M
- Total assets
- $12.2B
- Market cap
- $11.0B
- Operating margin
- 12.5%
- Net margin
- 8.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.9B
- Operating expenses
- $2.5B
- Operating income
- $356.6M
- Income tax
- $28.4M
- Net income
- $241.2M
- EPS (basic)
- $2.07
- EPS (diluted)
- $2.07
Balance sheet
- Total assets
- $12.2B
- Current assets
- $2.2B
- Total liabilities
- $4.9B
- Current liabilities
- $1.3B
- Shareholders’ equity
- $7.3B
Cash flow
- Operating cash flow
- $582.9M
- Investing cash flow
- -$17.4M
- Financing cash flow
- -$857.5M
- Net cash flow
- -$243.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $11.0B
- P/E ratio
- 48.5
- EPS (diluted)
- $2.07
- Dividend yield
- 0.28%
- Shares outstanding
- 109.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 1, 1972
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $241.2M in FY2025.
- Revenue grew 4% from FY2023 to FY2025.
- Trading 15% below its 52-week high.
- Pays a dividend yielding about 0.28% annually.
- Valued at a price-to-earnings (P/E) ratio of 48.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review REVVITY, INC..
Write a review
News about REVVITY, INC.
News & sentiment via Polygon.io
